Our large practice urology group has partnered with theralogix, a vitamin company to offer patients products that have been shown in study to help with various conditions.
Prosteon is a bone health supplement for men undergoing Androgen Deprivation Therapy (hormone therapy), or for anyone looking to support their bone health.
It can be ordered through:
A new national database study shows that the high-tech approach improves oncologic outcomes; this prompted a grand declaration from an expert.
Source: ‘End of Controversy’: Robotic Prostatectomy Is Winner
“Robotic prostatectomy has superior or at least equal oncologic efficacy and complication rates compared to open prostatectomy,” writes Michael O. Koch, MD, from the Indiana University School of Medicine in Indianapolis. “I believe the most current literature supports that view and this debate should finally be put to rest.”
This is Medscape’s summary of an editorial that my mentor at Indiana, wrote comparing open and robotic surgery for prostate cancer. He has performed thousands of operations with both techniques and points out how robotic surgery does cost more, although only about $2000 more at high volume centers.
I first switched to robotic prostatectomy in 2004 and these conclusions were apparent to many surgeons that adopted and became proficient with robotic prostatectomy over a decade ago.
The protective effect of frequent intercourse is strongest for low-risk prostate cancer.
An ejaculation frequency of 21 or more times per month at age 20–29 years and 40–49 years is associated with a significant 19% and 22% decreased risk of a PCa diagnosis, respectively, compared with a frequency of 4–7 times per month in adjusted analyses, Jennifer R. Rider, MD, of the Boston University School of Public Health, and colleagues reported. In addition, results showed that ejaculation frequency at age 20–29 years was significantly associated with intermediate-risk PCa. Men in this age group who had 13 or more ejaculations per month experienced a significant 27% reduction in the risk of a diagnosis of intermediate-risk PCa compared with those who had 4–7 ejaculations per month. Ejaculation frequency was not significantly associated with a diagnosis of high-risk PCa or regional/distant metastases, according to the investigators.
Source: Prostate Cancer Risk Lower in Men Who Ejaculate More – Renal and Urology News
Men often ask me about the effects of sexual activity on prostate cancer. This study shows that more frequent relations help prevent prostate cancer. The amount of activity needed to have this benefit seems high to me. Being active more than 2 of 3 days is much more than most men are currently experiencing.
I will need to add this to the list of things I tell men about how to stay healthy.
Tumors fall into 1 of 5 grade groups based on what pathologic findings indicate about prognosis.
Source: Simpler Prostate Cancer Grading System Proposed
I have been counseling men with prostate cancer on their treatment options for many years. One of the most difficult parts of diagnosing prostate cancer is explaining to the patient and family what his “cancer” means. I have started with the most important prognostic factors of gleason score and PSA to explain how their prostate cancer is compared to other men.
I’ve explained how the cancer scoring system goes from gleason 2 to 10, but really the least aggressive cancers have a gleason score of 6. There have been less than a handful of patients that have been diagnosed with a score of 5 in my career. For the thousands of men that I have counseled, I used to translate their gleason score from 1-4 with a 6 translating to a 1 and a 7 to either a 2 or 3. Fortunately the urology field is adapting a similar scoring system.
The new grading system simplifies the scoring to a scale of 1-5, with 1 being the least aggressive and 5 the most aggressive. The old gleason 7 was made of of 2 types, a less aggressive 3+4 and a more aggressive 4+3. This should help men and their loved ones better understand the type of prostate cancer they have.
Approximately 14 percent of men will be diagnosed with prostate cancer at some point in their lifetimes, according to the National Institutes of Health. Radiation therapy traditionally has been a primary treatment for the cancer, but one-fourth of men have a recurrence of prostate cancer within five years after the therapy. Now, a University of Missouri School of Medicine researcher has found that a complex procedure to remove the prostate achieves excellent long-term survival for men after radiation therapy has failed.
Source: Surgery improves survival rates for men with prostate cancer if radiation treatments fail
Men are often told that surgery can not be performed after radiation therapy. This article shows how men can have surgery for prostate cancer after failed radiation therapy.
I have performed many davinci robotic prostatectomies after failed therapies. Due to the effects of the radiation on the tissue surrounding the prostate, the risks of salvage surgery is much higher than surgery done as the original treatment. The biggest change is that the risk of life long incontinence goes up significantly.
I have also performed salvage robotic prostate surgery for failed HIFU and cryosurgery patients.
I am frequently asked about the changes to fluid that comes out of the penis during sexual activity and about the ability to have children.
Many years ago I described the changes for men to expect after prostatectomy for cancer.
Normally the testicles make sperm that travels through the vas deferens to reach the prostate where it mixes with most of the fluid from the prostate to make the ejaculate.
If you have a vasectomy, the vas defers is clipped so that sperm can not enter the prostate area and you become sterile. The amount of ejaculate during sexual activity remains the same.
With prostate removal, the ejaculate which is made from fluid from the prostate and seminal vesicles is also missing. Men can have an orgasm, but there will be no fluid that comes out with the orgasm as normal.
There may be a small amount of fluid that is thick that comes out during the excitement phase as before.
Some men also experience leakage of urine that comes from the bladder during the excitement or orgasm stage of sexual activity.
Prostate cancer patients with clinically localized tumors are more likely to die if they undergo radiotherapy rather than radical prostatectomy.
Radiotherapy for clinically-localized prostate cancer (PCa) is associated with an increased risk of overall and PCa-specific mortality compared with radical prostatectomy, according to a new systematic review and meta-analysis.
Dr. Nam’s group stated that, to their knowledge, their study represents the most comprehensive and up-to-date review of the literature comparing survival outcomes associated with radiotherapy and surgery.
Source: Surgery Offers Prostate Cancer Patients Better Survival Odds
This issue is frequently asked by patients. In the short run, surgery and radiation are both effective at controlling prostate cancer. Over time, most studies have shown that prostate cancer surgery is more effective than radiation at curing cancer.
PSA doubling time, a marker of cancer progression, increased from 28 to 76 months in prostate cancer patients performing exercise training.
“The exercise intervention resulted in marked physiological adaptations that aided weight regulation and increased fitness levels,” Dr. Hojman told Renal & Urology News. “PSA doubling time correlated with improved fitness, but not with weight loss. These findings suggest there is a fitness component that plays a role in the control of prostate cancer that is not related to weight.”
Source: Exercise Training May Delay PCa Progression – Renal and Urology News
I have been recommending exercise for my prostate cancer patients for many years. I usually recommend 30 minutes of aerobic exercise 3 times a week. In this study, 45 minutes of exercise 3 times a week led to the PSA going up slowly for patients that had regular exercise.
The U.S. Food and Drug Administration approved enzalutamide for the treatment of patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). At the prespecified interim analysis, a statistically significant improvement in overall survival was demonstrated for patients
Source: U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
I have been using enzalutamide in my patients who have metastatic disease proven by imaging or pathology and have progressed where hormonal therapy isn’t enough to keep the PSA near 0.